Atorvastatin + Evolocumab

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Conditions

Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Trial Timeline

Oct 1, 2013 → Jun 1, 2014

About Atorvastatin + Evolocumab

Atorvastatin + Evolocumab is a phase 3 stage product being developed by Amgen for Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events. The current trial status is completed. This product is registered under clinical trial identifier NCT01953328. Target conditions include Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events.

What happened to similar drugs?

8 of 20 similar drugs in Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events were approved

Approved (8) Terminated (2) Active (11)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01953328Phase 3Completed

Competing Products

20 competing products in Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

See all competitors